These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 19835562)
1. Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide. Bourgault S; Vaudry D; Dejda A; Doan ND; Vaudry H; Fournier A Curr Med Chem; 2009; 16(33):4462-80. PubMed ID: 19835562 [TBL] [Abstract][Full Text] [Related]
2. A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists. Ramos-Álvarez I; Mantey SA; Nakamura T; Nuche-Berenguer B; Moreno P; Moody TW; Maderdrut JL; Coy DH; Jensen RT Peptides; 2015 Apr; 66():26-42. PubMed ID: 25698233 [TBL] [Abstract][Full Text] [Related]
3. [Pituitary adenylate cyclase-activating polypeptide]. Gonzalez BJ; Basille M; Vaudry D; Fournier A; Vaudry H Ann Endocrinol (Paris); 1998 Dec; 59(5):364-405. PubMed ID: 9949891 [TBL] [Abstract][Full Text] [Related]
4. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland. Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629 [TBL] [Abstract][Full Text] [Related]
5. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals. Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855 [TBL] [Abstract][Full Text] [Related]
6. Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Bourgault S; Vaudry D; Botia B; Couvineau A; Laburthe M; Vaudry H; Fournier A Peptides; 2008 Jun; 29(6):919-32. PubMed ID: 18353507 [TBL] [Abstract][Full Text] [Related]
7. Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects. Doan ND; Bourgault S; Dejda A; Létourneau M; Detheux M; Vaudry D; Vaudry H; Chatenet D; Fournier A Biochem Pharmacol; 2011 Feb; 81(4):552-61. PubMed ID: 21114961 [TBL] [Abstract][Full Text] [Related]
8. Doxycycline exerted neuroprotective activity by enhancing the activation of neuropeptide GPCR PAC1. Yu R; Zheng L; Cui Y; Zhang H; Ye H Neuropharmacology; 2016 Apr; 103():1-15. PubMed ID: 26700245 [TBL] [Abstract][Full Text] [Related]
9. Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) and the PACAP-selective receptor in cultured rat astrocytes, human brain tumors, and in response to acute intracranial injury. Jaworski DM Cell Tissue Res; 2000 May; 300(2):219-30. PubMed ID: 10867818 [TBL] [Abstract][Full Text] [Related]
11. Novel splice variants of type I pituitary adenylate cyclase-activating polypeptide receptor in frog exhibit altered adenylate cyclase stimulation and differential relative abundance. Alexandre D; Vaudry H; Grumolato L; Turquier V; Fournier A; Jégou S; Anouar Y Endocrinology; 2002 Jul; 143(7):2680-92. PubMed ID: 12072402 [TBL] [Abstract][Full Text] [Related]
12. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor. Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136 [TBL] [Abstract][Full Text] [Related]
13. [Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system]. Hashimoto H Yakugaku Zasshi; 2002 Dec; 122(12):1109-21. PubMed ID: 12510388 [TBL] [Abstract][Full Text] [Related]
14. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC. Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681 [TBL] [Abstract][Full Text] [Related]
15. Modulation of AMPA receptor-mediated ion current by pituitary adenylate cyclase-activating polypeptide (PACAP) in CA1 pyramidal neurons from rat hippocampus. Costa L; Santangelo F; Li Volsi G; Ciranna L Hippocampus; 2009 Jan; 19(1):99-109. PubMed ID: 18727050 [TBL] [Abstract][Full Text] [Related]
16. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta. Scaldaferri ML; Modesti A; Palumbo C; Ulisse S; Fabbri A; Piccione E; Frajese G; Moretti C Endocrinology; 2000 Mar; 141(3):1158-67. PubMed ID: 10698193 [TBL] [Abstract][Full Text] [Related]
17. Distribution and functional characterization of pituitary adenylate cyclase-activating polypeptide receptors in the brain of non-human primates. Jolivel V; Basille M; Aubert N; de Jouffrey S; Ancian P; Le Bigot JF; Noack P; Massonneau M; Fournier A; Vaudry H; Gonzalez BJ; Vaudry D Neuroscience; 2009 May; 160(2):434-51. PubMed ID: 19236905 [TBL] [Abstract][Full Text] [Related]
18. Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor. Bourgault S; Vaudry D; Ségalas-Milazzo I; Guilhaudis L; Couvineau A; Laburthe M; Vaudry H; Fournier A J Med Chem; 2009 May; 52(10):3308-16. PubMed ID: 19413310 [TBL] [Abstract][Full Text] [Related]